Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expands By 5.6%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 4,340,000 shares, a growth of 5.6% from the October 15th total of 4,110,000 shares. Currently, 7.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 524,700 shares, the short-interest ratio is currently 8.3 days.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AGIO. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Raymond James restated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Scotiabank increased their price objective on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $52.33.

Agios Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ AGIO opened at $53.78 on Friday. The company has a market capitalization of $3.07 billion, a PE ratio of 4.73 and a beta of 0.75. Agios Pharmaceuticals has a twelve month low of $20.96 and a twelve month high of $62.58. The firm has a fifty day simple moving average of $46.44 and a 200 day simple moving average of $43.87.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of large investors have recently bought and sold shares of AGIO. ProShare Advisors LLC grew its stake in Agios Pharmaceuticals by 9.0% during the first quarter. ProShare Advisors LLC now owns 13,917 shares of the biopharmaceutical company’s stock worth $407,000 after purchasing an additional 1,152 shares during the period. Entropy Technologies LP bought a new stake in shares of Agios Pharmaceuticals in the 1st quarter valued at $286,000. State Board of Administration of Florida Retirement System lifted its position in shares of Agios Pharmaceuticals by 13.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 18,017 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 2,170 shares during the period. Vanguard Group Inc. boosted its stake in Agios Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 5,572,021 shares of the biopharmaceutical company’s stock worth $162,926,000 after acquiring an additional 44,583 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its holdings in Agios Pharmaceuticals by 1.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock worth $911,000 after purchasing an additional 540 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.